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Summary
Individuals with hemizygous germline fumarate hydratase (FH) mutations are predisposed to renal cancer. These tumors
predominantly exhibit functional inactivation of the remaining wild-type allele, implicating FH inactivation as a tumor-
promoting event. Hypoxia-inducible factors are expressed in many cancers and are increased in clear cell renal carcino-
mas. Under normoxia, the HIFs are labile due to VHL-dependent proteasomal degradation, but stabilization occurs under
hypoxia due to inactivation of HIF prolyl hydroxylase (HPH), which prevents HIF hydroxylation and VHL recognition. We
demonstrate that FH inhibition, together with elevated intracellular fumarate, coincides with HIF upregulation. Further, we
show that fumarate acts as a competitive inhibitor of HPH. These data delineate a novel fumarate-dependent pathway for
regulating HPH activity and HIF protein levels.S I G N I F I C A N C E
The inherited disorder hereditary leiomyomatosis renal cell carcinoma (HLRCC), which is characterized by germline FH mutation, is
associated with cutaneous and uterine leiomyomata and renal cancer. While FH inactivation is associated with these pathologies,
the causative molecular mechanisms are unknown. Herein, we demonstrate an increase in HIF and HIF-regulated transcripts in FH-
inactivated and fumarate-treated cells, and we show elevated HIF protein levels in FH renal tumors. Genetic inactivation of FH and
blockade of the TCA cycle necessitates a metabolic reliance upon glycolysis. Most tumor cells are dependent upon glycolysis for
survival and concomitantly overexpress HIF, a transcriptional regulator of glycolysis and the hypoxic response. Fumarate-mediated
HIF upregulation, coupled with inactivated FH-driven adaptation to glycolysis, together create an environment permissive for tumori-
genesis.Introduction
Through genetic linkage analysis of afflicted families, fumarate
hydratase (FH) deficiency has been implicated in the dominant
hereditary syndrome hereditary leiomyomatosis renal cell carci-
noma (HLRCC). Germline mutation of FH predisposes to cuta-
neous and uterine leiomyomata (smooth muscle tumors) and
renal cell cancer (Kiuru et al., 2001; Launonen et al., 2001;
Tomlinson et al., 2002; Toro et al., 2003). Although heterozy-
gote carriers exhibit reduced FH enzymatic activity but areCANCER CELL : AUGUST 2005 · VOL. 8 · COPYRIGHT © 2005 ELSEVIER INotherwise phenotypically normal, the remaining functional al-
lele is mutated or lost in nearly all cutaneous, uterine, and renal
tumors arising in these individuals (Alam et al., 2003; Tomlinson
et al., 2002).
Although somatic FH inactivation predisposes to tumor for-
mation, biallelic germline mutation of FH causes fumarate defi-
ciency syndrome, an ultimately fatal disorder resulting in severe
neurological impairment (Bourgeron et al., 1994; Gellera et al.,
1990). The disparate outcome between complete and partial
germline inactivation of FH function may be explained by itsC. DOI 10.1016/j.ccr.2005.06.017 143
A R T I C L Erole in metabolism. FH plays an essential role in the mitochon-
drial tricarboxylic acid (TCA), or Krebs cycle, by catalyzing the
conversion of fumarate to malate. A primary function of the
TCA cycle is the oxidation of pyruvate, supplied by the glyco-
lytic pathway, for energy. The abrogation of FH activity has pro-
found cellular consequences that are incompatible with normal
embryologic development. Thus, the pronounced neurological
defects associated with biallelic germline FH deficiency can be
explained by the high energy demands of the developing ner-
vous system during embryogenesis coupled with the depen-
dence of neurons upon oxidative phosphorylation (Eng et al.,
2003; Shulman et al., 2004).
Hypoxia-inducible factor (HIF) is a central regulator of oxy-
gen homeostasis. HIF-1α or HIF-2α, together with HIF-1β, or
ARNT, forms an active transcription complex that upregulates
numerous target genes that play roles in glycolysis, angiogen-
esis, metastasis, and survival (for review, see Semenza, 2003).
HIF gene products collectively promote adaptation to hypoxia,
and HIF-1α (or in some cases HIF-2α) is overexpressed in a
majority of primary tumors, cancer cell lines, and metastases
(Birner et al., 2000; Talks et al., 2000; Zhong et al., 1999). HIF-
1α and HIF-2α are both labile under normoxic conditions, due
to proteasomal degradation following their oxygen-dependent
ubiquitination by a ubiquitin ligase complex targeted to HIF by
the von Hippel-Lindau (VHL) protein (Iwai et al., 1999; Maxwell
et al., 1999; Ohh et al., 2000). VHL recognition of HIF requires
the enzymatic hydroxylation of two conserved proline residues
on HIF mediated by HIF prolyl hydroxylase (HPH) (Bruick and
McKnight, 2001; Epstein et al., 2001; Ivan et al., 2001; Jaak-
kola et al., 2001; Yu et al., 2001). HPH activity requires the
cofactors ascorbate and iron and the cosubstrates 2-oxoglu-
tarate (2-OG) and molecular oxygen. This elegant system ex-
plains the basis for HIF stabilization under hypoxia, as HPH
function and subsequently VHL recognition of hypo-hydroxyl-
ated HIF is compromised in the absence of oxygen.
Germline alteration of VHL is the basis for a hereditary can-
cer syndrome in which affected individuals are at risk to de-
velop multiple angiogenic tumors, including clear cell renal cell
carcinoma (CCRCC) (Gnarra et al., 1994; Kaelin and Maher,
1998). Almost universally, tumors arising in VHL patients or
sporadic CCRCC have lost the remaining VHL allele (Gnarra
et al., 1994; Prowse et al., 1997) and display high HIF protein
levels and coincident upregulation of HIF-dependent tran-
scripts (Iliopoulos et al., 1996; Wiesener et al., 2001). The link
between HIF expression and CCRCC is further validated by the
finding that reintroduction of VHL into VHL-deficient cell lines
suppresses their ability to form tumors in vivo (Iliopoulos et al.,
1995), an effect ascribed to reduced HIF expression (Kondo et
al., 2003, 2002; Maranchie et al., 2002).
Inherited neoplastic syndromes are also associated with mu-
tation of the succinate dehydrogenase (SDH) complex (Astuti
et al., 2001; Baysal et al., 2000; Niemann and Muller, 2000),
which catalyzes the conversion of succinate to fumarate in the
TCA cycle. Interestingly, tumors harboring SDH mutations ex-
hibit elevated HIF protein levels and associated hypoxia-induc-
ible transcripts (Gimenez-Roqueplo et al., 2001), and individuals
may be predisposed to early onset renal cancer (Vanharanta et
al., 2004). Therefore, genetic inactivation of SDH and FH with
subsequent accumulation of succinate and fumarate is corre-
lated with cancer development, and particularly with a predis-
position for renal cancer. Although a role for HIF in VHL-defi-144cient CCRCC is well established, there are no data supporting
a similar role for HIF in HLRCC tumors. In the current study,
we demonstrate that HLRCC renal tumors exhibit elevated ex-
pression of HIF-1 and HIF-2 proteins, as well as the protein
product of the HIF-regulated gene Glut-1. Furthermore, we
show that fumarate, and to a lesser extent succinate, abrogate
VHL recognition of HIF by impairing HPH activity. Finally, we
demonstrate that fumarate inhibits HPH activity by competing
with its cosubstrate 2-OG. These data demonstrate a direct
link between fumarate dysregulation and HPH inactivation.
Results
HIF proteins are overexpressed in HLRCC renal tumors
Although a role for HIF has not been previously implicated in
HLRCC renal tumors, we considered whether alteration of HIF
expression is associated with these neoplasms. Tumor speci-
mens from seven HLRCC patients were fixed and prepared for
immunohistochemical analysis. Representative staining from
normal and tumor tissue is shown in Figure 1. Both HIF-1 and
HIF-2 proteins are uniformly overexpressed in tumor tissue. In-
formation pertaining to germline FH status of these HLRCC
patients has been previously reported (Toro et al., 2003; Wei et
al., 2005). A summary of HIF protein expression and germline
and somatic FH genetic status of these tumors is presented in
Table 1. The majority of tumor specimens (five of seven con-
firmed cases) exhibited loss of heterozygosity (LOH) for FH,
a result consistent with previous findings (Alam et al., 2003;
Tomlinson et al., 2002).
FH inhibition and fumarate synergistically upregulate
and stabilize HIF protein
The data in Figure 1 suggested a correlation between loss of
FH and overexpression of HIF proteins in HLRCC-associated
tumors. We sought to explore this relationship further on a mo-
lecular level. As there are no established HLRCC cell lines, we
emulated this phenotype by exogenously adding fumarate to
cultured cells in combination with 3-nitropropionic acid (3-NPA),
an established dual inhibitor of SDH and FH (Coles et al., 1979;
Porter and Bright, 1980). 3-NPA was used because of the lack
of a specific pharmacologic inhibitor of FH. A549 cells were
treated with the indicated concentration of 3-NPA and increas-
ing concentrations of fumarate. HIF protein levels increased in
a dose-dependent manner when both agents were added
simultaneously, although a slight, but reproducible increase
was evident with 3-NPA alone (Figure 2A). To further examine
the kinetics of the fumarate-mediated HIF induction, we treated
cells with 3-NPA and 2.5 mM fumarate and examined time-
dependent accumulation of HIF. A modest increase in HIF pro-
tein levels was observed within 4 hr of treatment (Figure 2B,
upper panel). Longer exposure of the same film (lower panel)
shows that detectable upregulation of HIF occurs within 2 hr
of treatment. Similar results were obtained using different es-
terified forms of fumarate (data not shown).
The combination of 3-NPA and fumarate did not alter the
level of HIF mRNA (data not shown), suggesting that a post-
transcriptional mechanism was responsible for this phenome-
non. Since the α subunit of HIF is tightly regulated posttransla-
tionally by protein degradation, we examined whether fumarate
modulated HIF stability. Cells were treated as indicated (Figure
2C), and the protein synthesis inhibitor cycloheximide (CHX)CANCER CELL : AUGUST 2005
A R T I C L EFigure 1. HIF proteins are overexpressed in FH re-
nal tumors
Tissues were prepared for immunohistochemical
detection of HIF-1 and HIF-2 proteins as de-
scribed. Representative HIF staining from a
HLRCC renal tumor is shown. Normal kidney tis-
sue removed from the same patient served as
a matched negative control. Antibody controls
are also shown. All views are 20× magnification.concentrations of fumarate alone (Figure 3B, left panel). Com-
Table 1. Summary of HIF protein expression and FH mutational status in renal
tumor tissue from seven HLRCC patients
Age Sex HIF-1α HIF-2α FH germline mutation LOH 1q42
63 F 2+ 1+ C823T yes
23 M 1+ 1+ C823T NA
32 F 3+ 1+ G del@1339 yes
32 M 3+ 1+ A del@1162 no
24 F 1+ 1+ C172T yes
27 F 3+ 0 G138+ 1C yes
38 M 3+ 1+ C568T yes
HIF-1α and HIF-2α were quantified by immunohistochemistry, relative to normal
kidney tissue. HIF staining was scored as follows: 3+, >75% cells positive; 2+,
50%–75% cells positive; 1+, 10%–50% cells positive; 0, <10% cells positive.
NA, data not available.was used to determine the apparent half-life of HIF protein. In
untreated cells, HIF was extremely unstable, with a half-life of
6 min. In marked contrast, 3-NPA and fumarate increased the
half-life of HIF almost 5-fold to 28 min.
2-OG antagonizes fumarate- and succinate-mediated
upregulation of HIF
Since 3-NPA is also a known inhibitor of SDH (Coles et al.,
1979), we considered whether elevated succinate levels might
affect HIF protein levels, especially in light of the finding that
hereditary mutations in SDH lead to HIF-expressing paragan-
gliomas and pheochromocytoma (Gimenez-Roqueplo et al.,
2001), and a recent report that SDH siRNA promotes elevated
HIF protein levels in 293 cells (Selak et al., 2005). We therefore
tested whether succinate, either alone or in combination with
3-NPA, affected HIF expression in our cell model. Although
succinate alone failed to increase HIF protein levels, combina-
tion of succinate and 3-NPA did weakly induce HIF, but less
robustly than did 3-NPA and fumarate (Figure 3A).
Another TCA cycle intermediate, 2-OG, is an essential co-
substrate for HPH. We therefore considered whether the activ-
ity of fumarate (or succinate) could be countered by increasing
the level of 2-OG. Indeed, 2-OG completely abrogated HIF-1
induction mediated either by 3-NPA and fumarate, or by highCANCER CELL : AUGUST 2005bination of fumarate and 3-NPA also induced HIF-2 in a 2-OG-
sensitive manner (Figure 3B, right panel). Finally, 2-OG abro-
gated HIF induction caused by 3-NPA and succinate (Figure
3C), suggesting that upregulation of HIF by either succinate or
fumarate impacts a pathway utilizing 2-OG.
Since 3-NPA inhibits both SDH and FH, we treated cells with
siRNA specific for FH to verify that endogenous FH is involved
in the 3-NPA-mediated HIF induction. Quantitative RT-PCR
was used to verify siRNA-mediated downregulation of FH
mRNA. FH siRNA reduced FH mRNA level in A549 cells by
over 80%, while no reduction was observed with a nonspecific
(NS) siRNA control (Figure 4A, upper left panel). FH siRNA re-
duced FH enzyme activity by more than 50% (Figure 4A, upper
right panel). To confirm that FH knockdown results in increased
fumarate levels, we utilized nuclear magnetic resonance (NMR)
to monitor changes in intracellular fumarate, succinate, lactate,
and glucose following FH siRNA (Figure 4A, lower panel). FH
siRNA alone resulted in a doubling of intracellular fumarate
(from 0.30 to 0.57 mole/g protein), while addition of 5 mM
exogenous fumarate (for 4 hr) to cells previously treated with
FH siRNA produced a further 10-fold increase in intracellular
fumarate. Neither FH siRNA alone nor the combination of FH
siRNA and fumarate altered intracellular succinate, although
both treatments resulted in a dramatic increase in intracellular
glucose (4- to 6-fold) and lactate (60%). These data strongly
suggest that loss of FH is sufficient to upregulate glycolysis.
Western blotting with an antibody specific for FH confirmed a
marked reduction in FH protein expression in both A549 and
Caki cells following FH siRNA (Figure 4A, middle panel). Treat-
ment of both cell lines with FH siRNA (in the absence of exoge-
nous fumarate) induced a dose-dependent increase in HIF pro-
tein (Figure 4B, upper panel). FH siRNA also enhanced the
ability of fumarate to increase HIF (Figure 4B, lower panel).
Fumarate inhibits HIF prolyl hydroxylation
by competitively inhibiting HPH
Since the activity of fumarate can be overcome by elevating
the level of 2-OG, an essential cosubstrate for HPH, we next
asked whether its ability to induce HIF is VHL dependent. We
examined the effects of fumarate upon HIF protein levels in
a VHL-deficient renal carcinoma cell line, UMRC2, and in its145
A R T I C L EFigure 2. FH inhibition coupled with fumarate addition upregulates and stabilizes HIF protein
A: A549 lung carcinoma cells were treated for 6 hr with the FH inhibitor 3-NPA (750 M) in combination with the indicated increasing amounts of fumarate.
Nuclear extracts were probed first for HIF-1 and then for topoisomerase to confirm equal loading.
B: A549 cells were treated with the combination of 3-NPA and 2.5 mM fumarate for the indicated times. The longer exposure (bottom panel) illustrates HIF
induction after a 2 hr treatment. The blot was reprobed for topoisomerase to confirm equal loading.
C: The left panel represents untreated cells and serves as a control. Right panel: A549 cells were treated as in B for 6 hr, whereupon CHX was added for
the indicated times, and nuclear extracts were probed for HIF-1. These data are depicted quantitatively in the bottom panel.transfected counterpart, UMRC2/VHL, which stably expresses
FLAG-VHL (Isaacs et al., 2002). Combination of 3-NPA and fu-
marate increased HIF protein levels in UMRC2/VHL, and 2-OG
antagonized this induction (Figure 5A, left panel). However,
when this experiment was repeated in VHL-deficient UMRC2
cells, fumarate and 3-NPA were not able to induce HIF expres-
sion, and 2-OG was not able to diminish HIF expression (Figure
5A, right panel). To exclude any potential effects of fumarate
upon VHL localization, cytoplasmic VHL expression was moni-
tored from control or fumarate-treated cells. As shown in Figure
5A (lower left panel), there was no change in cytoplasmic VHL
content in response to these treatments. Thus, these data sug-
gest that VHL is required for both fumarate-mediated HIF in-
duction and 2-OG-mediated HIF reduction.
We next considered whether fumarate increased HIF protein
levels by interfering with HPH function. First, we examined
whether fumarate reduced HPH activity in vivo. A549 cells were
treated with the indicated agents, and we monitored the hy-
droxylation state of HIF with an antibody specific for hydroxyl-
ated HIF (Kageyama et al., 2004). The hydroxylation status of
HIF was markedly reduced by 3-NPA/fumarate (Figure 5B, up-
per panel). As a positive control for HIF hydroxylation, cells
were treated with the proteasome inhibitor PS-341 (PS lane),
which permits accumulation of hydroxylated HIF, while treat-
ment with the HPH inhibitor dimethyloxalylglycine (DMOG)
served as a negative control. The lower panel of Figure 5B il-
lustrates the total level of HIF protein following each treatment.
We then tested whether the impact of fumarate on HIF hy-
droxylation could be recapitulated in a cell-free system. To do
so, we utilized an in vitro VHL capture assay (Tuckerman et al.,1462004; Bruick and McKnight, 2001; Jaakkola et al., 2001). While
the association of VHL with a HIF peptide in the absence of
exogenously added HPH cofactors (control lane) is undetecta-
ble, addition of those cofactors (UT lane) markedly enhances
association of HIF and VHL (Figure 5C, top panel). Strikingly,
fumarate, and to a lesser degree succinate, significantly re-
duced this association. As we expected, 2-OG reversed the
inhibitory effects of fumarate and succinate in this assay (see
Figure S1 in the Supplemental Data available with this article
online). Finally, we used a chemically hydroxylated peptide to
verify that fumarate has a direct impact on HPH activity. Fu-
marate does not impair VHL association with the hydroxylated
HIF peptide (Figure 5C, lower panel). Lastly, the specificity of
this assay was confirmed by showing that a HIF peptide in
which the two proline residues were mutated to alanine failed
to bind VHL under any circumstances (data not shown).
Our data strongly support the premise that fumarate is a
potent inhibitor of HPH. To determine directly whether fuma-
rate and/or succinate inhibited HPH activity, we used purified
HPH-2 (McNeill et al., 2005), the primary enzyme responsible
for regulating HIF levels under normoxia (Berra et al., 2003), in
a similar VHL capture assay. Because this assay uses purified
enzyme, it obviates the possibility of off-pathway artifacts. Ini-
tial reaction velocities were determined at the indicated con-
centrations of 2-OG and fumarate, succinate, N-oxalylglycine
(N-OG), or buffer alone. At high concentrations (2 mM), both
fumarate and succinate inhibited HPH-2 activity (data not
shown). However, dose-response curves demonstrated that fu-
marate more potently inhibited HPH-2 activity than did succi-
nate (Figure 5D). From these data, the IC value for fumarate50
CANCER CELL : AUGUST 2005
A R T I C L EFigure 3. 2-oxoglutarate antagonizes the fumarate- and succinate-medi-
ated upregulation of HIF
A: A549 cells were treated with 3-NPA in combination with the indicated
concentrations of fumarate or succinate, and the level of nuclear HIF-1
was monitored. The blot was probed for topoisomerase to confirm equal
loading.
B: Cells were treated as indicated, and the ability of exogenously added
2-oxoglutarate (2-OG) to affect the fumarate-mediated induction of HIF-1
and HIF-2 protein was assessed.
C: Cells were treated as indicated (2.5 mM fumarate or succinate, 750
M 3-NPA), and the ability of 2-OG to affect the fumarate- or succinate-
mediated induction of HIF was determined.was determined to be 6.6 M (±2.6), while the IC50 for succi-
nate was approximately 3-fold higher, with a value of 21 M
(±8). For comparison, the ability of the HPH inhibitor N-OG
(Jaakkola et al., 2001) to inhibit enzymatic activity in this assay
is shown (IC50 = 1.3 M).
To better assess the nature of fumarate- and succinate-
mediated inhibition of HPH, we determined dose-response
curves for 2-OG in the presence or absence of low concentra-
tions of fumarate (Figure 5E, left panel) or succinate (Figure
5E, right panel). The data are illustrated as double reciprocal
Lineweaver-Burke plots. The presence of either fumarate or
succinate alters the apparent Km for 2-OG (intercept with x
axis) without affecting the Vmax (intercept with y axis), indicat-
ing direct competitive inhibition with respect to 2-OG. From
these data, the Ki value of fumarate was determined to be 2.6
M (±0.2), while the Ki for succinate was approximately 3-fold
higher (9 ± 0.1 M).
Fumarate increases expression of HIF-regulated genes
Our data demonstrate that a modest (2-fold) increase in intra-
cellular fumarate, caused by loss of FH expression, is sufficient
to promote accumulation of HIF by competitively inhibiting the
HPH cosubstrate 2-OG. The marked increase of intracellular
glucose and lactate following FH knockdown suggested thatCANCER CELL : AUGUST 2005the accumulating HIF protein is transcriptionally active and
may be driving a metabolic conversion to glycolysis. To exam-
ine this question more closely, we treated A549 cells either with
cobalt (a positive control), with 3-NPA/fumarate, or with FH
siRNA, and we monitored the HIF-regulated transcripts Glut-1
and VEGF (Iyer et al., 1998) by quantitative RT-PCR. All treat-
ments resulted in more than a 2-fold increase in Glut-1 mRNA
(Figure 6A). These treatments also elicited an increase in VEGF
mRNA, with 3-NPA/ fumarate causing the largest induction (al-
most 3-fold). These data are consistent with a recent report
demonstrating upregulation of hypoxia-induced transcripts in
FH-deficient uterine leiomyomata (Pollard et al., 2005), and
they support our hypothesis that HIF protein accumulated sub-
sequent to FH inhibition or loss is transcriptionally active.
Treatment of cells with FH siRNA elicited a small, but repro-
ducible increase in VEGF mRNA. To validate the ability of FH
siRNA to increase VEGF expression, we monitored the level of
secreted VEGF protein by ELISA. siRNA treatment resulted in
a modest induction of VEGF protein (2-fold and 1.8-fold, re-
spectively) in A549 and Caki cells (Figure 6B). Although these
data suggest that fumarate accumulation induces transcrip-
tionally active HIF protein, both VEGF and Glut-1 transcripts
can be induced independently from HIF (Barthel et al., 1999;
Baudino et al., 2002; Okajima and Thorgeirsson, 2000). To fur-
ther test whether the observed increase in these genes was
HIF dependent, we used siRNA against ARNT (Isaacs et al.,
2004) to reduce the levels of this essential HIF cofactor, whose
dimerization with HIF is required for formation of a competent
transcriptional complex (Jiang et al., 1996; Wood et al., 1996).
ARNT siRNA treatment dramatically reduced ARNT protein ex-
pression in A549 cells (Figure 6C, right panel). Strikingly, treat-
ment with ARNT siRNA reduced the basal level of Glut-1
mRNA and essentially abrogated Glut-1 induction elicited by
either cobalt or 3-NPA/fumarate (Figure 6C, left panel). These
data strongly suggest that fumarate-dependent elevation of
Glut-1 transcripts is mediated via HIF transcriptional activity.
Finally, we wished to determine if a similar phenomenon
could be demonstrated in HLRCC tumor specimens. Thus, we
examined Glut-1 protein expression in three HLRCC tumor
samples and three normal kidney specimens by immunohisto-
chemistry. In the normal specimens, Glut-1 positivity was ob-
served only in contaminating red blood cells (as expected),
while strong focal staining of tumor cell membranes for Glut-1
was seen in three of three HLRCC specimens. Figure 6D de-
picts Glut-1 staining in a representative HLRCC and normal
kidney specimen. These data highlight the significant impact
of FH loss on HIF protein levels and transcriptional activity in
HLRCC.
Discussion
In HLRCC, individuals are predisposed to cutaneous and uter-
ine leiomyomata and renal cancer, yet the mechanism(s) con-
tributing to these pathologies are unknown. We illustrate herein
that HLRCC renal tumors overexpress not only HIF-1 and
HIF-2 proteins, but also products of their target genes. As a
result of our in vitro data, we suggest that excess intracellular
fumarate, accumulating in the tumor cells in response to loss
of FH, is partially responsible for this phenomenon. While it
remains to be determined whether HIF upregulation is required
and/or sufficient for the development of HLRCC-associated re-147
A R T I C L EFigure 4. Knockdown of FH expression with siRNA induces fumarate-sensitive HIF accumulation and enhances cellular glucose uptake and lactic acid pro-
duction
A: Upper left panel: RT-PCR was utilized to verify the ability of FH-siRNA to downregulate FH mRNA in A549 cells. A nonspecific (NS) siRNA served as a
negative control, and message levels are represented as fraction of NS control. Upper right panel: an assay measuring endogenous FH activity was
performed as described, utilizing A549 cells transfected with either NS or FH siRNA. FH activity is expressed as nmole NADPH formed/g protein/min.
Determinations for each condition were performed in triplicate, and the mean and standard error for each condition is shown. Middle panel: immunoblot
analysis of FH protein level following transfection of the indicated cells with FH siRNA. Tubulin is shown for verification of equal protein loading. Bottom
panel: A549 cells were either left untreated (control) or transfected on succeeding days with FH siRNA in the absence or presence of 5 mM fumarate (for
4 hr on last day). Samples were then processed for NMR analysis, and intracellular concentrations of the indicated metabolites are shown.
B: Upper panel: A549 or Caki-1 cells were transfected either with control siRNA (100 nM) or with the indicated concentrations of FH siRNA, and HIF was
detected from nuclear lysates 20 hr following transfection. Lower panel: A549 cells were transfected with 60 nM FH siRNA and then treated with the
indicated concentrations of fumarate the following day (for 4 hr), at which time HIF expression was determined following cell lysis.nal cancers, we demonstrate that raising the level of intracellu-
lar fumarate upregulates VEGF and Glut-1 transcripts in a HIF-
dependent manner and that HLRCC tumors express Glut-1.
These data suggest that HIF expression confers a survival ad-
vantage contributing to the tumorigenic phenotype of HLRCC.
This report demonstrates a link between dysregulation of FH
and modulation of HPH function. The stability and expression
of HIF proteins are, in large part, regulated by the concerted
actions of HPH and VHL. We clearly demonstrate that fumarate
abrogates the association between HIF and VHL, due to de-
creased HPH-2-dependent enzymatic hydroxylation of HIF.
Moreover, we present conclusive evidence that fumarate di-
rectly impairs HPH-2 function by acting as a competitive inhibi-
tor of 2-OG. Succinate also upregulates HIF by inhibiting its
proline hydroxylation (Selak et al., 2005), but in vitro enzyme
kinetic analysis proves it to be a weaker antagonist of 2-OG, a
finding in keeping with its reduced potency (relative to fuma-
rate) in causing intracellular HIF accumulation in A549 cells.
Although our study emphasizes the effects of fumarate-
dependent HPH inhibition on the HIF pathway, we cannot ex-
clude the possibility that failure to degrade other, as yet unde-
scribed HPH substrates may contribute to development of
HLRCC. Indeed, the presence of a hydroxyproline binding
pocket in the VHL protein (Hon et al., 2002) suggests that other148VHL substrates similarly require proline hydroxylation as a pre-
requisite for binding to VHL. Their fate in the context of HPH
inhibition remains to be examined. One must also consider the
possibility that inhibition of 2-OG-dependent prolyl hydroxyla-
tion by elevated TCA cycle intermediates may favor tumorigen-
esis that is independent of HIF accumulation. Thus, although
experimentally induced loss of SDH activity in 293 embryonal
kidney cells has been shown to result in HIF accumulation via
HPH inhibition (Selak et al., 2005), a more recent study in PC12
cells identifies alternative, HPH-dependent, but HIF-indepen-
dent, pathways by which loss of SDH promotes tumorigenesis
(Lee et al., 2005). Although the importance of HIF accumulation
per se for tumorigenesis may depend on the tissue or cell type
affected, endogenous levels and/or activity of HPH are gen-
erally thought to be limiting (Knowles et al., 2003), suggesting
that small fluctuations in levels of either 2-OG or its competitive
inhibitors could have profound effects upon HPH activity in
vivo. Collectively, these recent findings highlight the potential
importance of HPH in tumorigenesis.
A near-universal feature of tumor cells is their apparent reli-
ance upon glycolysis, even under normoxia, a phenomenon
termed the Warburg effect (Warburg, 1956). While the precise
mechanisms underlying this metabolic shift are unclear, several
lines of evidence point to HIF as a pivotal control element. HIFCANCER CELL : AUGUST 2005
A R T I C L EFigure 5. Fumarate upregulates HIF by inhibiting HIF prolyl hydroxylase activity
A: Parental VHL-deficient UMRC2 cells and UMRC2/VHL cells expressing stably transfected FLAG-VHL were treated as indicated, and the effects of fuma-
rate and 2-OG upon nuclear HIF protein levels were assessed. VHL protein was immunodetected from UMRC2/VHL cytoplasmic lysates.
B: A549 cells were treated with the indicated agents and treated with proteasome inhibitor (PS) 1 hr prior to nuclear lysis as described. Resultant blots were
probed with an antibody specific for hydroxylated HIF (upper panel). The lower panel demonstrates the level of nuclear HIF protein from these samples.
C: A VHL capture assay utilizing biotinylated HIF peptide was performed as described. Top panel: the assay was performed in the presence of cofactors
and the indicated millimolar concentrations of fumarate (F) or succinate (S), and resultant blots were probed for FLAG (VHL). The control lane (con)
represents the assay in the absence of added cofactors, while the untreated (UT) lane contains all required cofactors. Lower panel: the same assay was
repeated utilizing a chemically hydroxylated peptide and increasing concentrations of fumarate.
D: Purified HPH-2 enzyme was utilized in an HPH assay as described, and the ability of either fumarate or succinate to inhibit HPH activity was assessed.
The inhibitory effect of the HPH inhibitor N-oxalylglycine is shown for comparison.
E: The HPH assay was repeated with low concentrations of either fumarate (left panel) or succinate (right panel), and the inhibitory effects of these
substrates upon HPH function in the presence of increasing concentrations of 2-OG were determined.plays an essential role in sustaining glycolytic metabolism by
transactivating several key substrates and enzymes of this
pathway (Iyer et al., 1998; Minchenko et al., 2002; Obach et
al., 2004; Ryan et al., 1998; Semenza et al., 1996). Blockade
of the TCA cycle, either by hypoxia or by genetic inactivation
of key enzymes such as FH and SDH, should enhance cellular
reliance upon glycolysis and select for cells demonstrating
upregulation of this pathway. Indeed, our data demonstrating
dramatically elevated intracellular glucose and lactate levels
following FH siRNA-dependent doubling of intracellular fuma-
rate provides direct experimental evidence supporting this hy-
pothesis. Our findings identify biallelic loss of FH as a single
gene defect capable of inducing the Warburg effect. Further
experimentation is needed to fully explore the link between
dysregulation of the TCA cycle and tumorigenesis and to more
thoroughly elucidate the roles of HIF and HPH in this process.
Experimental procedures
Cell culture and treatments
A549 and Caki-1 were obtained from the American Type Culture Collection
and cultured in Dulbecco’s modified Eagle’s medium/F12 supplementedCANCER CELL : AUGUST 2005with 10% fetal calf serum, 2 mM glutamine, 5 mM HEPES. UMRC2 clear
cell renal carcinoma cells were provided by Dr. M. Lerman (NCI, Frederick,
MD). C2/VHL cells express a stably integrated VHL plasmid (Isaacs et al.,
2002) and were grown in 400 g/ml G418. Cells were treated, as indicated,
with the following agents: monoethyl ester fumararic acid (MEF), 3-NPA,
dimethyl 2-OG, diethyl succinate, cobalt, ascorbic acid, all purchased from
Sigma. Fumarate and succinate were administered as cell-permeable ester-
ified derivatives. DMOG and N-OG were purchased from AG Scientific, and
PS-341 was from Millenium Pharmaceuticals (Cambridge, MA).
HLRCC phenotypic and genotypic assessment
Patients with suspected or confirmed HLRCC were evaluated in the Uro-
logic Oncology Branch of the National Cancer Institute. Evaluation included
history and physical examination, cutaneous examination and biopsy of cu-
taneous leiomyomata, abdominal and pelvic CT scan, and renal and uterine
ultrasound. Three of the seven patients had renal surgery at the NCI, while
the other four had surgery at outside institutions. The pathology of all of the
renal tumors was reviewed by two pathologists (M.M. and C.T.-C.). Normal
and tumor tissue was manually microdissected, as described (Zhuang et
al., 1995), and subjected to proteinase K digestion, and DNA was extracted
using the QIAamp DNA Micro Kit (QIAGEN Inc., Valencia, CA), according to
the manufacturer’s specifications. Sample DNA was PCR amplified using
the genetic polymorphic markers D1S517, D1S2670, D1S2785, D1S304,
D1S547, D1S2842, and D1S2811 (Research Genetics, Huntsville, AL) for149
A R T I C L EFigure 6. Fumarate increases the expression of HIF-regulated transcripts and proteins
A: A549 cells were treated as indicated, and quantitative RT-PCR was performed from total RNA utilizing primers specific for Glut-1, VEGF, or FH mRNA to
determine the relative levels of message following these treatments. Values were calculated from the threshold cycle (Ct) number, as described.
B: A549 and Caki-1 were transfected with either control or FH siRNA, and secreted VEGF protein was detected from the conditioned medium by ELISA.
C: Left panel: A549 cells were transfected on successive days with either control or ARNT siRNA, and cells were treated as indicated for 8 hr in the presence
or absence of ARNT siRNA. RNA was harvested, and Glut-1 message was determined utilizing RT-PCR as in A. The experiment was repeated three times,
and mean values and standard errors are shown. Right panel: an identical set of cells was transfected, and total protein was harvested. ARNT levels were
determined by immunoblot analysis, and equal protein loading was verified by tubulin protein levels.
D: Normal renal tissue and HLRCC tumor tissue were stained for Glut-1 protein by immunohistochemistry. Brown pigment reflects positive staining. In normal
tissue, Glut-1 staining is only observed in red cell membranes. An antibody control is also shown.LOH of region 1q42-44. Denatured PCR products were analyzed using the
Genetic Analyzer GeneScan Analysis Program (Applied Biosystems). Each
sample was processed in duplicate with negative controls, peaks corre-
sponding to allelic expression were measured, and allelic loss was calcu-
lated. The designation of LOH was assigned to allelic imbalance values
equal to or below 0.6.
Immunohistochemistry
Immunohistochemical stains were performed on formalin-fixed, paraffin-
embedded tissue. Briefly, 5 mm sections were deparaffinized and rehy-
drated. Antigen retrieval was performed by steaming the slides in DAKO
target retrieval solution (DAKO, Carpinteria, CA) for 10 min. Endogenous
peroxidase activity was blocked using 3% hydrogen peroxide solution for
5 min. The antibodies and dilutions used for immunohistochemical labeling
were as follows: antibodies specific for HIF-1 α (NB 100-123, clone H1α67;
1:1000) and HIF-2 α (NB 100-132, clone 190b; 1:400) were from Novus
Biologicals, and polyclonal rabbit antibody to Glut-1 (A3536; 1:100) was
from DAKO. Detection of immunolabeling was performed using the Cata-
lyzed Signal Amplification system for HIF-1, and Envision Plus (both from
DAKO) for HIF-2 and Glut-1, according to the manufacturer’s recommenda-
tions. Diaminobenzidine was utilized as the chromogen. Negative controls,
in which the primary antibody was replaced with PBS, were run with all of
the samples.
Immunoblot analysis
All HIF immunoblots were performed on nuclear extracts. For subcellular
fractionations, cells were washed with low-salt lysis buffer and fractionated
as described (Isaacs et al., 2002). Equivalent amounts of nuclear extract
were separated by 4%–20% SDS-PAGE (Bio-Rad), and the blots were sub-150sequently probed for either HIF-1 (Transduction) or HIF-2 (Novus). For de-
tection of hydroxylated HIF, 40 g nuclear extract was probed with a rabbit
antibody that specifically recognizes HIF hydroxylation at proline 564 (Ka-
geyama et al., 2004). For the immunodetection of stably transfected FLAG-
tagged VHL, total cell lysates were prepared as described (Isaacs et al.,
2004) and probed for FLAG (Sigma). For detection of FH protein, a rabbit
anti-FH antibody (Autogen Bioclear, UK) was utilized. For protein visualiza-
tion, horseradish peroxidase-linked secondary antibodies were used with
the ECL protein detection system (Pierce). Experiments were performed in
duplicate and normalized with antibodies to topoisomerase II (nuclear ex-
tracts) or tubulin (cytoplasmic and total extracts; Sigma).
HPH-2 purification and in vitro VHL capture assay
Biotinylated wild-type or proline-hydroxylated peptides (corresponding to
HIF residues 556–574) were synthesized (American Peptide Company, Sun-
nyvale, CA), dissolved in sterile H2O (500 g/ml), and incubated with strep-
tavidin beads (Pierce ImmunoPure) at 4°C for 2 hr. The beads were washed
twice with VHL binding buffer (20 mM Tris [pH 8], 100 mM NaCl, 1 mM
EDTA, 0.5% NP40) and three times with reaction buffer (20 mM Tris [pH
7.5], 5 mM KCl, 1.5 mM MgCl2). For each condition, 2 g peptide/20 l
beads was aliquoted into separate tubes and reaction buffer was added,
along with cofactors (500 M α-ketoglutaric acid, 500 M L-ascorbic acid,
50 M ferrous chloride). Unless otherwise specified, all chemicals were pur-
chased from Sigma. The beads and HPH cofactors were mixed at room
temperature for 15 min in reaction buffer. Prior to this incubation, any inhibi-
tors or competing factors were added to the appropriate tubes. For in vitro
experiments involving fumarate or succinate competition with 2-OG, the
buffered, disodium forms of these agents were used. Separate in vitro
translated (IVT) reactions (Promega) were the source for the HPH proteinCANCER CELL : AUGUST 2005
A R T I C L E(HPH-2 plasmid was kindly provided S. McKnight, University of Texas Medi-
cal Center, Dallas, TX) and FLAG-VHL (Isaacs et al., 2002). A 10 l aliquot
of IVT HPH-2 was added to the bead-peptide mixture for 1 hr at 30°C.
Subsequently, the beads were washed with VHL binding buffer and 10 l
FLAG-VHL IVT was added to the beads overnight at 4°C. The beads were
washed, SDS Laemmli buffer was added, the samples were boiled and sub-
jected to SDS-PAGE, and resultant blots were probed for FLAG.
As the source for purified HPH-2 protein, an N-terminally truncated HPH-2
sequence (amino acids 181–426) was subcloned into pET28a(+) and ex-
pressed in BL21(DE3), as described (McNeill et al., 2005). Purification of the
His6-tagged protein was accomplished with HisBind resin (Novagen), and
cleavage of the affinity tag was achieved with thrombin (Novagen). Desalt-
ing on a 300 ml Superdex-75 column (Amersham Pharmacia Biotech)
yielded 95% pure protein. For the VHL capture experiments with purified
HPH protein, a slightly modified protocol was used (see Supplemental
Data). Reactions remained linear over the time course of the reaction, and
initial reaction velocities were calculated from the slope. Calibration of pep-
tide hydroxylation was achieved by mixing known amounts of the equiva-
lent hydroxylated HIF-1α peptide with the nonhydroxylated peptide, thus
allowing the signal obtained from captured [35S]-pVHL to be calibrated
against the hydroxylated peptide.
HIF half-life determination
A549 cells were treated for 6 hr with the combination of the FH inhibitor
3-NPA and fumarate. CHX was then added to the medium, and the cells
were fractionated and lysed after the indicated times of CHX treatment. HIF
was visualized from nuclear extracts, the films were quantitated by densito-
metric analysis, and the half-life was calculated using Excel.
RNA interference
Four different siRNAs corresponding to the FH coding sequence were syn-
thesized (Qiagen), and 50–100 nM siRNA was transfected into Caki cells
using previously described conditions (Isaacs et al., 2004). The next day,
nuclear extracts were monitored for HIF-1 induction. The most effective
FH siRNA sequence, as verified by RT-PCR (CCAGGATTATGGTCTTGAT,
corresponding to residues 321–339 of FH coding sequence), was used for
subsequent experiments. RNA interference for ARNT was similarly per-
formed as previously described (Isaacs et al., 2004). A549 cells were trans-
fected with ARNT siRNA in succession 24 hr apart, at which time the cells
were treated with the indicated agents prior to RNA harvest. Control siRNA
consisted of a mouse FITC-conjugated sequence (Qiagen). Control siRNA was
used in each experiment in which either FH- or ARNT-specific siRNA was
employed, in order to control for transfection conditions and RNA admin-
istration.
Real-time RT-PCR
RNA was isolated using the RNeasy RNA Isolation kit according to the man-
ufacturer’s instructions (Qiagen). For reverse transcription, 200 ng of total
RNA was used in a reaction mixture containing 1× TaqMan RT buffer (Ap-
plied Biosystems) and Multiscribe Reverse Transcriptase. Reverse tran-
scription was performed for 10 min at 25°C, 30 min at 48°C, and 5 min at
95°C using the PE9700 thermal cycler (Applied Biosystems). Real-time PCR
primers were designed using Primer Express software (Applied Biosystems)
(see Supplemental Data for information on primers and PCR conditions).
The number of PCR cycles to reach the fluorescence threshold value is the
cycle threshold (Ct). Ct values for the control (18S rRNA) and genes of
interest were determined, and relative RNA levels were calculated by the
comparative Ct method as described by the manufacturer. Experiments
were performed in duplicate.
FH enzyme assay
FH activity was determined essentially as described (Hatch, 1978). Briefly,
cell lysate containing a defined amount of total protein (30–100 g) was
added to a final volume of 200 l assay buffer consisting of 25 mM HEPES-
KOH (pH 7.5), 0.4 mM NADP, 4 mM MgCl2, 5 mM KH2PO4, 0.4 units/ml
NADP:malic enzyme (EC 1.1.1.4), and 10 mM fumarate. Increases in absor-
bance at 340 nm due to formation of NADPH were monitored at room tem-
perature in UV-transparent 96-well flat bottom microtiter plates (Costar) in
an ELx808 microplate reader (Bio-Tek). FH activity is expressed as nmoleCANCER CELL : AUGUST 2005NADPH formed/g protein/min. Samples lacking either cellular protein or
fumarate were used to determine blank values.
NMR analysis of intracellular metabolites
To analyze intracellular levels of fumarate, succinate, lactate, and glucose,
A549 cells were transfected with FH siRNA (100 nM) as previously de-
scribed, with the modification that the cells were transfected twice in suc-
cession 24 hr apart. For each condition, six 6 cm plates were treated iden-
tically. When present, exogenous fumarate (5 mM) was added to cells for
4 hr prior to cell lysis, the day following the second transfection. The cells
were washed twice with PBS and lysed in 6% cold perchloric acid. Follow-
ing a 10 min centrifugation, the supernatant containing the metabolites was
transferred to another tube, while the remaining protein precipitate was
used for quantitation. The supernatant was neutralized with 10% potassium
hydroxide, and the samples were centrifuged to remove the salt precipitate.
Neutralized cell extracts were freeze dried and reconstituted in 0.6 ml deu-
terium oxide (Sigma, UK), 0.5 ml of which was placed in 5 mm NMR tubes.
For chemical shift calibration and quantification, 50 l of 1 mM sodium
3-trimethylsilyl-2,2,3,3-tetradeuteropropionate (Sigma, UK) was added to
the samples. 1H NMR spectra were obtained using a Bruker 600 MHz
(Bruker Biospin, Coventry, UK) spectrometer with repetition time of 6.3 s
and 384 averages. A pulse and collect with water suppression NMR se-
quence was used. All data were acquired under identical experimental con-
ditions, and all shown metabolites from each sample were obtained from
the same data collection. Metabolite concentrations are expressed as
mole/g total protein.
VEGF ELISA
A549 or Caki-1 cells were treated as indicated. Following transfection of FH
siRNA, the medium was replaced, and the cells were allowed to incubate
for 16 hr. For fumarate-treated cells, medium was collected from A549 and
Caki-1 cells following 9 hr and 6 hr (respectively) of treatment. A VEGF
ELISA kit (R&D Systems, MN) was used to assess secreted VEGF levels
from a 200 l aliquot of medium. Each sample was harvested for protein,
which was used to normalize VEGF levels. An experiment for each condition
was carried out at least once in triplicate.
Supplemental data
The Supplemental Data include Supplemental Experimental Procedures
and one figure and can be found with this article online at http://www.
cancercell.org/cgi/content/full/8/2/143/DC1/.
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